Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | Chief Medical Officer | February 06, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date February 06, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2036-02-06 | Direct | 125,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000 F1: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 9, 2026 20:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006619 · wk-form4_1770688454.xml · derivative · entry 1 Arora Puneet S. · CIK 0002035933 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 17:34 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000004 · wk-form4_1740609251.xml · derivative · entry 1 Arora Puneet S. · CIK 0002035933 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests 25% on the one year anniversary of February 21, 2025 and 1/48th monthly thereafter. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 18:12 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001516551-24-000084 · wk-form4_1725484100.xml · derivative · entry 1 Arora Puneet S. · CIK 0002035933 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-09-03 F1 · derivative.exercise_date: The stock option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.